Patent Approved for Potential Type 1 Diabetes Vaccine
PRV-101 is a polyvalent vaccine candidate for acute coxsackievirus infection and potentially a preventive vaccine for type 1 diabetes
Provention Bio, Inc. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled, "Multi-CBV Vaccine for Preventing or Treating Type 1 Diabetes."
The patent application covers methods of use involving the development of a coxsackievirus B (CVB) vaccine for the prevention and/or treatment of type 1 diabetes (T1D).
This is important news since various studies indicate that approximately 50 percent of all T1D cases could be triggered by a CVB infection in early childhood.
Type 1 diabetes, once known as juvenile diabetes or insulin-dependent diabetes, is a multifactorial disease resulting in the autoimmune destruction of the insulin-producing β-cells of the pancreas, says the Mayo Clinic.
T1D requires lifelong treatment with daily insulin injections and often leads to vascular and neurological complications reducing the quality of life and life expectancy.
PRV-101 is being developed as a polyvalent vaccine for acute coxsackievirus infection and potentially as the first-ever vaccine designed to prevent T1D.
PRV-101 is currently in an IND-enabling stage prior to the initiation of the first-in-human clinical study.
Based on this research, which was recently the subject of a peer-reviewed paper in Expert Review of Vaccines: Developing a Vaccine for Type 1 Diabetes by Targeting Coxsackievirus B.
Ashleigh Palmer, Provention Bio's Co-Founder and Chief Executive Officer, said in a press release, "As we advance PRV-101 towards the clinic, we will continue to aggressively pursue opportunities to strengthen the intellectual property estate surrounding this technology and the use of a polyvalent CVB vaccine to prevent T1D."
Previous diabetes vaccine news:
For more information regarding PRV-101, please visit Proventionbio.